Human MHC non-restricted cytotoxic T-cell line TALL-104

Drug Overview

The human MHC non-restricted cytotoxic T-cell line TALL-104 (often referred to simply as TALL-104) is a unique, allogeneic cell-based immunotherapy designed to target and destroy a broad range of cancer cells. Originally derived from a 2-year-old patient with T-cell acute lymphoblastic leukemia (T-ALL), this cell line has been modified for use as a potent antitumor agent.

The “MHC non-restricted” nature of TALL-104 is its defining characteristic: it can recognize and kill cancer cells without needing a genetic “match” (Major Histocompatibility Complex compatibility) between the donor cells and the patient. This makes it a potential “off-the-shelf” adoptive cell therapy.

• Generic Name: TALL-104 (ABIO-0501).
• Drug Class: Adoptive Cell Therapy / Allogeneic T-lymphocyte therapy.
• Target: Broad-spectrum tumor antigens (non-specific).
• Mechanism: Direct cytotoxicity via apoptotic and necrotic pathways.
• Route of Administration: Intravenous (IV), Intraperitoneal (IP), or Intralesional (direct injection).
• FDA Approval Status: Investigational. As of March 2026, TALL-104 is not FDA-approved. It has primarily been studied in Phase I and Ib trials for metastatic breast cancer, ovarian cancer, and malignant gliomas.

What Is It and How Does It Work? (Mechanism of Action)

TALL-104 cells function as “universal hunters.” They possess characteristics of both Cytotoxic T-lymphocytes (CTLs) and Natural Killer (NK) cells, allowing them to attack tumors through multiple biological “weapons.”

1. MHC-Independent Targeting

Normally, T-cells can only “see” cancer if the cancer displays markers on a specific genetic scaffold (MHC). Many cancers hide by removing these scaffolds. TALL-104 cells bypass this requirement, using receptors like NKp46 and NKG2D to identify cancer cells based on “stress signals” rather than genetic markers.

2. Molecular Level Mechanisms

• Direct Lysis: Upon contact with a tumor cell, TALL-104 triggers lytic granule exocytosis, releasing perforins and granzymes. Perforins punch holes in the cancer cell membrane, while granzymes enter to initiate a “self-destruct” sequence.
• Dual Death Pathways: The cells induce both apoptosis (programmed cell death) and necrosis (cell bursting).
• Cytokine Storm (Targeted): Interaction with tumor cells stimulates TALL-104 to secrete Interferon-gamma (IFN-$\gamma$) and Tumor Necrosis Factor (TNF), which help recruit and activate the patient’s own stagnant immune system.
• Safety via Irradiation: Before being infused into a patient, TALL-104 cells are lethally irradiated (40 Gy). This ensures they cannot multiply or cause leukemia in the patient, but they remain metabolically active and “deadly” to cancer for several days.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for TALL-104.

The therapy is strictly available through clinical trials. Historical and current areas of research include:

• Refractory Metastatic Breast Cancer: For patients who have failed multiple lines of chemotherapy.
• Malignant Gliomas (Brain Cancer): Studied for local administration into the tumor bed because these cells can traffic through brain tissue.
• Ovarian Epithelial Carcinoma: Investigated via intraperitoneal (abdominal) delivery.
• Veterinary Oncology: TALL-104 has shown significant success in treating spontaneous tumors in pet dogs, serving as a “bridge” to human clinical trials.

Dosage and Administration Protocols

Because the cells are irradiated and do not divide in the body, they must be administered in high, repeated doses to maintain an effective “army” against the tumor.

Clinical Efficacy and Research Results

As of 2026, TALL-104 is regarded as a promising “biological spark” that can initiate a broader immune response.

• Antitumor Activity: In Phase I trials for metastatic breast cancer, TALL-104 was well-tolerated and showed signs of biological activity, including increased circulating levels of IFN-$\gamma$ and NK cell activity in the patients.
• Immunological Memory: Evidence suggests that even though TALL-104 cells die off, their attack on the tumor releases debris that “trains” the patient’s own immune system to recognize the cancer, potentially leading to long-term protection.
• Blood-Brain Barrier: Research has demonstrated that with specialized disruption techniques (like osmotic BBBD), TALL-104 cells can cross into the central nervous system to target brain tumors.

Safety Profile and Side Effects

The safety profile of TALL-104 is generally favorable compared to chemotherapy, as the cells specifically spare normal, healthy tissues.

Common Side Effects:

• Infusion Reactions: Fever, chills, and “rigors” (shaking) during or shortly after the IV drip.
• Flu-like Symptoms: Fatigue, muscle aches, and headache as cytokines are released.
• Gastrointestinal: Transient nausea or mild diarrhea.

Serious Risks/Precautions:

• Hepatotoxicity: Some trials noted transient increases in liver enzymes (transaminitis) which typically resolve on their own.
• Steroid Interference: Patients requiring high-dose steroids (like Dexamethasone) for other conditions are often ineligible, as steroids deactivate TALL-104 cells and stop them from killing cancer.
• Graft-vs-Host (Theoretically): While irradiation minimizes this risk, any allogeneic (foreign) cell therapy carries a theoretical risk of the donor cells attacking the host, though this has not been a major issue in TALL-104 trials.

Research Areas

In Stem Cell and Regenerative Medicine, TALL-104 is being studied as a tool for “Ex Vivo Bone Marrow Purging.” In patients undergoing autologous stem cell transplants (using their own cells), TALL-104 can be used in the lab to “clean” the harvested marrow of any hidden cancer cells before they are given back to the patient. Because the cells are MHC-non-restricted, they don’t need to be tailored to each specific donor.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Cardiac/Pulmonary Screen: To ensure the patient can handle the cytokine-induced stress of infusion.
• Liver Function Tests (LFTs): Baseline monitoring is essential due to the potential for transient liver stress.

“Do’s and Don’ts” List:

• DO expect a mild fever; it is often a sign that the “killer cells” are successfully engaging with the tumor.
• DO maintain hydration during the infusion days to help your kidneys process the cell-clearing byproducts.
• DON’T take anti-inflammatory steroids (like Prednisone) unless directed by your study doctor, as they may “turn off” the treatment.
• DON’T worry about the leukemia origin; the lethal irradiation process is a strict safety standard that prevents the cells from ever becoming a “new” cancer.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. TALL-104 is an investigational agent and is not currently approved by the US FDA. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for participation in research.